The Regulator

200,000: that is how many low-income Arkansans could lose Medicaid coverage after the Trump administration refused to renew the state’s 13-year-old Medicaid expansion waiver under a new federal budget rule. The Centers for Medicare and Medicaid Services (CMS) rejected Arkansas’s request to renew its ARHOME (Arkansas Health and Opportunity for Me) waiver, first granted in 2013 and set to expire December 31, 2026, saying the arrangement no longer complies with a “budget neutrality” policy CMS issued in June 2026 under guidance SMD 26-003. That guidance, adopted using authority from the 2025 reconciliation law, now requires CMS to certify prospectively that a Medicaid waiver will not increase federal spending beyond what traditional Medicaid would cost, replacing the retroactive checks CMS previously relied on. A 2014 Government Accountability Office review found Arkansas’s waiver spending ran nearly $800 million above traditional Medicaid costs over its first three years, a figure CMS has cited to justify the tighter standard. Arkansas has asked CMS for a two-year extension to design a replacement program instead of the five-year renewal it originally sought; Governor Sarah Huckabee Sanders’s office called the standoff an opening for “conservative healthcare reform,” while a Boston University health law professor called it “a sneaky way to cut Medicaid expansion.” Confidence: High on the federal budget-neutrality policy itself, drawn from CMS’s own guidance. Medium on the Arkansas-specific coverage and dollar figures, which reflect KFF Health News’s reporting rather than a CMS-published state table. Sources: Informational Bulletin SMD 26-003, Medicaid.gov, CMS Takes Bold New Approach to Stewarding Medicaid Demonstration Project Spending, Centers for Medicare and Medicaid Services, Trump Team’s Use of Arcane Budget Rule Threatens Medicaid Coverage, KFF Health News.

2,465: that is how many measles cases the CDC (Centers for Disease Control and Prevention) has confirmed nationwide this year, the most since 1991, as a federal committee decides this month whether the United States keeps the measles elimination status it has held since 2000. The United States National Verification Committee for the Elimination of Measles, Rubella, and Congenital Rubella Syndrome, chaired by Noel T. Brewer, is reviewing case data, outbreak durations, and viral genome sequencing this month to determine whether any chain of measles transmission has continued unbroken for 12 months or longer, the technical threshold for losing elimination status; the committee’s findings go to the World Health Organization’s Pan American Health Organization, whose Regional Verification Commission announces its own decision in November 2026. CDC’s own tracking shows 38 active outbreaks nationwide, one more than the prior week, with 93 percent of this year’s patients unvaccinated or of unknown vaccination status and 7 percent hospitalized; no deaths have been reported in 2026. An outbreak in Utah that began in June 2025 had already run longer than the 12-month threshold as of early August. Confidence: High on the case and outbreak counts, drawn directly from CDC. Medium on the review timeline and stakes, which reflect a committee member’s own public account rather than a CDC or PAHO statement, since neither agency has yet issued its determination. Sources: Measles Cases and Outbreaks, Centers for Disease Control and Prevention, What my colleagues and I will look for as we assess U.S. measles elimination status, STAT.

Schedule V: that is where the DEA (Drug Enforcement Administration) wants to move three widely prescribed insomnia drugs, cutting them loose from the tightest controlled-substance tier they currently share with Xanax and Valium. The DEA published a proposed rule August 11, 2026 to reclassify suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq), a class of drugs called dual orexin receptor antagonists, from Schedule IV to Schedule V of the Controlled Substances Act, the least restrictive tier for drugs with accepted medical use. The proposal follows a scientific and medical evaluation by the Department of Health and Human Services that found the drugs carry low abuse potential relative to other Schedule IV substances and do not produce physical or psychological dependence; a Schedule V classification would ease prescribing, dispensing, and registration burdens that currently apply to the drugs. The public comment period runs through September 10, 2026. Idorsia, which markets Quviviq, publicly welcomed the proposal as a step toward improving patient access to the drug class. Confidence: High. This run reviewed multiple direct accounts of the Federal Register notice’s contents, including the manufacturer’s own securities disclosure, though the Federal Register page itself returned an access error on direct fetch. Sources: DEA Proposes Rescheduling DORAs, Sleep Review, Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule, Idorsia Media Release.

150 months: that is the prison sentence a Houston-area physician received this month after prosecutors said her cash-only clinic issued prescriptions for more than 3 million opioid pills. Maryam Qayum, 68, of Montgomery County, Texas, who owned, operated, and was the sole prescriber at Recare Health Clinic in Kingwood, was sentenced August 5, 2026 to 12.5 years in federal prison for conspiracy to unlawfully distribute controlled substances, after pleading guilty in March 2026. Prosecutors said Qayum ran Recare as a cash-only pill mill from 2022 to 2025, selling prescriptions for high-strength oxycodone and hydrocodone to street-level dealers she and her staff referred to as “providers,” often without a legitimate medical purpose and sometimes without ever seeing the patient. Two co-defendants have already been sentenced in the case: Melvin Sampson of Houston received 210 months in June 2026, and nurse practitioner Tomi-Ko Bowers received 96 months the same month. Confidence: High. The Department of Justice’s and DEA’s own releases state the sentence, scheme, and defendants directly. Sources: Texas Physician Sentenced to 12 Years in Prison for Operating a Houston-Area Pill Mill, U.S. Department of Justice, Texas Physician Sentenced to 12 Years in Prison for Operating a Houston-Area Pill Mill, Drug Enforcement Administration.

Six: that is how many senators, three from each party, introduced legislation this month to rewrite the rules for one of the largest drug-discount programs in the country. Senators John Boozman (R-Arkansas), Jerry Moran (R-Kansas), Shelley Moore Capito (R-West Virginia), Tammy Baldwin (D-Wisconsin), Tim Kaine (D-Virginia), and John Hickenlooper (D-Colorado), members of the Senate’s Bipartisan 340B Working Group, introduced the SUSTAIN 340B Act on August 5, 2026. The bill would codify hospitals’ and clinics’ use of contract pharmacies to dispense discounted 340B drugs, without imposing the numeric or geographic caps some manufacturers have sought, while requiring those pharmacies to register and submit to audits; require covered entities to publish a standard financial assistance policy for patients at or below 200 percent of the federal poverty level; create an independent, third-party data clearinghouse to catch duplicate discounts; give the Department of Health and Human Services new audit and removal authority over noncompliant covered entities; and phase out drugmakers’ rebate-model pilots within one year while barring insurers from discriminating against 340B providers. The bill authorizes $3 million a year for five years for oversight and $9 million a year for four years for implementation. Confidence: High. This run reviewed a sponsoring senator’s own press release directly. Sources: Senate 340B Bipartisan Working Group Introduces Comprehensive 340B Reform Legislation, Senator John Boozman, Senators introduce bipartisan 340B legislation, AHA News.

60 days: that is how fast CMS wants to move from FDA (Food and Drug Administration) market approval to a final national Medicare coverage decision for certain breakthrough medical devices, under a pathway it proposed this month. CMS and FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway, formalized in a CMS procedural notice (CMS-3487-NC) published August 7, 2026, with public comments due October 13, 2026. For eligible FDA Breakthrough-designated Class II and Class III devices, FDA, CMS, and the manufacturer would coordinate starting at the earliest pre-submission stage so a device’s clinical trials generate data usable for both FDA authorization and Medicare coverage at once; under the pathway, CMS could issue a proposed national coverage determination the same day as FDA authorization, with a goal of finalizing it roughly 60 days later for Class II devices and 90 days later for Class III devices, replacing a gap that today can stretch for years. Confidence: High on the pathway’s mechanics, drawn from CMS’s and FDA’s own announcements. Low on its real-world effect on patient access or cost, since no device has yet moved through it. Sources: Regulatory Alignment for Predictable and Immediate Device Coverage Pathway (CMS-3487-NC) Procedural Notice, Centers for Medicare and Medicaid Services, CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices, U.S. Food and Drug Administration.